Gland Pharma

Eli Lilly plans to introduce Tirzepatide, marketed as Mounjaro, to India in 2025, targeting type 2 diabetes and obesity. The move aligns with the company's strategy to expand its portfolio in India, considering local affordability and value. Eli Lilly has been operating in India since 1993, collaborating with local firms for its diabetes portfolio, and aims to address India's growing healthcare challenges.

Eli Lilly plans to launch Tirzepatide (Mounjaro) in India in 2025, targeting type 2 diabetes and obesity. The company is optimistic about the Indian market due to rising disease burdens and health expenditure. Mounjaro's global Q3 2024 sales were over $3.1 billion, and pricing in India will be competitive, reflecting its efficacy.

Gland Pharma received FDA approval for latanoprost ophthalmic solution, 0.005% (2.5 mL Fill), bioequivalent to Xalatan, used for high eye pressure/intraocular pressure. Expected to launch in FY25, with US sales of ~USD 111.6 million by December 2023.

Gland Pharma secures US FDA approval for Latanoprost Ophthalmic Solution, targeting high intraocular pressure in glaucoma and ocular hypertension patients. The product is bioequivalent to Xalatan and plans to launch in FY 2025. US sales reached $111.6 million in 2023.

Gland Pharma Limited received USFDA approval for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), bioequivalent to Xalatan, treating high intraocular pressure in glaucoma or ocular hypertension patients. The product segment generated $111.6 million in US sales for the twelve months ending December 2023. Gland Pharma plans to launch the product through marketing partners in fiscal year 2025, aiming to strengthen its position in the US pharmaceutical market.

India's pharmaceutical industry is rapidly advancing in cancer drug development, driven by rising cancer cases and government initiatives like GST reductions on cancer drugs. Key companies like Beta Drugs, Shilpa Medicare, Gland Pharma, Venus Remedies, Pfizer, and Zydus Lifesciences are leading in innovation and global expansion, making cancer-focused pharma stocks a compelling investment opportunity.